Vaccine protection of the mother, the fetus, neonates and infants

Madison L. Wallace; Ken S. Rosenthal; Madison L. Wallace; Ken S. Rosenthal

doi:10.3934/Allergy.2024007

AIMS Allergy and Immunology

2024, Volume 8, Issue 2: 124-145. doi: 10.3934/Allergy.2024007

Previous Article Next Article

Review

Vaccine protection of the mother, the fetus, neonates and infants

Madison L. Wallace ¹,
Ken S. Rosenthal ^{1,2,3
,
,}

1.
Augusta University/University of Georgia Medical Partnership, Athens GA 30602
2.
University of Georgia, Athens, GA 30602
3.
Northeastern Ohio Medical University, Rootstown, OH 44272

Received: 15 March 2024 Revised: 21 June 2024 Accepted: 26 June 2024 Published: 03 July 2024

Pregnant women, the fetus, neonates, and young infants are at an increased risk for serious diseases from many infections due to their immunocompromised or immunonäive statuses. Vaccines are available for many diseases, but not all of the serious infectious diseases for which these individuals are at risk. Some of these vaccines can be administered to the mother either prior to or during pregnancy. The antibodies that are generated can benefit the mother, the fetus, and the neonate. Other vaccines can be administered to the neonate soon after birth to elicit important protections. This review outlines the available vaccines and the need and potential for new vaccines for pathogens that challenge pregnant women, the fetus, neonates, and the infant.
- vaccine,
- neonate,
- fetus,
- infant,
- pregnant,
- virus,
- infection
Citation: Madison L. Wallace, Ken S. Rosenthal. Vaccine protection of the mother, the fetus, neonates and infants[J]. AIMS Allergy and Immunology, 2024, 8(2): 124-145. doi: 10.3934/Allergy.2024007

Related Papers:

Abstract

Pregnant women, the fetus, neonates, and young infants are at an increased risk for serious diseases from many infections due to their immunocompromised or immunonäive statuses. Vaccines are available for many diseases, but not all of the serious infectious diseases for which these individuals are at risk. Some of these vaccines can be administered to the mother either prior to or during pregnancy. The antibodies that are generated can benefit the mother, the fetus, and the neonate. Other vaccines can be administered to the neonate soon after birth to elicit important protections. This review outlines the available vaccines and the need and potential for new vaccines for pathogens that challenge pregnant women, the fetus, neonates, and the infant.

Acknowledgments

The authors wish to acknowledge their colleagues and the reviewers who helped to ensure the quality and development of this manuscript.

Conflict of interest

The authors declare no commercial or financial relationships that could be construed as a potential conflict of interest.

Author contributions

KSR and MLW both contributed to the conceptualization, researching, writing, reviewing and editing of this manuscript.

References

[1]	Chan MY, Smith MA (2018) Infections in pregnancy. Comprehensive Toxicology . Amsterdam: Elsevier Science 232-249. https://doi.org/10.1016/B978-0-12-801238-3.64293-9
[2]	Khan AM, Morris SK, Bhutta ZA (2017) Neonatal and perinatal infections. Ped Clin North America 64: 785-798. https://doi.org/10.1016/j.pcl.2017.03.008
[3]	Etti M, Calvert A, Galiza E, et al. (2022) Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol 226: 459-474. https://doi.org/10.1016/j.ajog.2021.10.041
[4]	Kurasawa K (2023) Maternal vaccination-current status, challenges, and opportunities. J Obstet Gynaecol Res 49: 493-509. https://doi.org/10.1111/jog.15503
[5]	Engmann C, Fleming JA, Khan S, et al. (2020) Closer and closer? Maternal immunization: current promise, future horizons. J Perinatol 40: 844-857. https://doi.org/10.1038/s41372-020-0668-3
[6]	Mackin DW, Walker SP (2021) The historical aspects of vaccination in pregnancy. Best Practice Res Clin Obstetrics Gyn 76: 13-22. https://doi.org/10.1016/j.bpobgyn.2020.09.005
[7]	Psarris A, Sindos M, Daskalakis G, et al. (2019) Immunizations during pregnancy: How, when and why. Eur J Obstetrics Gyn Reprod Biol 240: 29-35. https://doi.org/10.1016/j.ejogrb.2019.06.019
[8]	Giles ML, Way SS, Marchant A, et al. (2023) Maternal vaccination to prevent adverse pregnancy outcomes: An underutilized molecular immunological intervention?. J Mol Biol 435: 168097. https://doi.org/10.1016/j.jmb.2023.168097
[9]	Centers for Disease Control, U.S.A. Immunization Schedules. Available from: https://www.cdc.gov/vaccines/schedules/index.html
[10]	Centers for Disease Control, U.S.A. Pregnancy and Vaccination. Available from: https://www.cdc.gov/vaccines/pregnancy/index.html
[11]	(2021) Centers for disease control and preventionEpidemiology and Prevention of Vaccine-Preventable Diseases. “The Pink Book”. Washington: D.C. Public Health Foundation.
[12]	FDAVaccines Licensed for Use in the United States. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states
[13]	Strikas RA (2015) Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years--United States, 2015. MMWR Morb Mortal Wkly Rep 64: 93-94. https://doi.org/10.1111/ajt.13293
[14]	Centers for Disease ControlGuidelines for vaccinating pregnant women. Available from: https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/guidelines.html#Passive%20Immunization%20During%20Pregnancy
[15]	Zhang HQ, Zhang QY, Yuan ZM, et al. (2023) The potential epidemic threat of Ebola virus and the development of a preventive vaccine. J Biosaf Biosecur 5: 67-78. https://doi.org/10.1016/j.jobb.2023.05.001
[16]	Malik S, Kishore S, Nag S, et al. (2023) Ebola virus disease vaccines: development, current perspectives and challenges. Vaccines 11: 268. https://doi.org/10.3390/vaccines11020268
[17]	Woolsey C, Geisbert TW (2021) Current state of Ebola virus vaccines: A snapshot. PLoS Pathog 17: e1010078. https://doi.org/10.1371/journal.ppat.1010078
[18]	Zhang J, Zhang XF, Huang SJ, et al. (2015) Long-term efficacy of a hepatitis E vaccine. N Engl J Med 372: 914-922. https://doi.org/10.1056/NEJMoa1406011
[19]	WHOHepatitis E (2023). Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-e
[20]	Ciglenecki I, Rumunu J, Wamala JF, et al. (2022) The first reactive vaccination campaign against hepatitis E. Lancet Inf Dis 22: 1110-1111. https://doi.org/10.1016/S1473-3099(22)00421-2
[21]	Centers for Disease ControlMalaria vaccines. Available from: https://www.cdc.gov/malaria/php/public-health-strategy/malaria-vaccines.html
[22]	Björkman A, Benn CS, Aaby P, et al. (2023) RTS, S/AS01 malaria vaccine—proven safe and effective?. Lancet Infect Dis 23: e318-e322. https://doi.org/10.1016/S1473-3099(23)00126-3
[23]	Verma A, Anand A, Patel VA, et al. (2024) Breaking the malaria barrier: The WHO-approved R21/Matrix-M vaccine and its global impact-an editorial. Ann Med Surg (Lond) 86: 1824-1827. https://doi.org/10.1097/MS9.0000000000001648
[24]	McIntosh EDG (2020) Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. Ther Adv Vaccines Immunother 8. https://doi.org/10.1177/2515135520923887
[25]	De la Maza LM, Darville TL, Pal S (2021) Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?. Expert Rev Vaccines 20: 421-435. https://doi.org/10.1080/14760584.2021.1899817
[26]	Murray SM, McKay PF (2021) Chlamydia trachomatis: Cell biology, immunology and vaccination. Vaccine 39: 2965-2975. https://doi.org/10.1016/j.vaccine.2021.03.043
[27]	Wagenlehner FME, Naber KG (2019) A step further in a vaccine for Escherichia coli. Lancet Infect Dis 19: 565-567. https://doi.org/10.1016/S1473-3099(19)30069-6
[28]	Kowarik M, Wetter M, Haeuptle MA, et al. (2021) The development and characterization of an E. coli O25B bioconjugate vaccine. Glycoconj J 38: 421-435. https://doi.org/10.1007/s10719-021-09985-9
[29]	Mayer RL, Verbeke R, Asselman C, et al. (2022) Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes. Nat Commun 13: 6075. https://doi.org/10.1038/s41467-022-33721-y
[30]	Haese EC, Thai VC, Kahler CM (2021) Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea. Vaccines 9: 804. https://doi.org/10.3390/vaccines9070804
[31]	Jefferson A, Smith A, Fasinu PS, et al. (2021) Sexually transmitted Neisseria gonorrhoeae infections-update on drug treatment and vaccine development. Medicines (Basel) 8: 11. https://doi.org/10.3390/medicines8020011
[32]	Lin EY, Adamson PC, Klausner JD (2021) Epidemiology, Treatments, and vaccine development for antimicrobial-resistant Neisseria gonorrhoeae: Current strategies and future directions. Drugs 81: 1153-1169. https://doi.org/10.1007/s40265-021-01530-0
[33]	Johnson B (2023) GSK's gonorrhea vaccine receives fast-track designation to expedite clinical trials. Nature Med 29: 2146-2147. https://doi.org/10.1038/d41591-023-00069-9
[34]	Scully IL, Timofeyeva Y, Illenberger A, et al. (2021) Performance of a four-antigen Staphylococcus aureus vaccine in preclinical models of invasive S. aureus disease. Microorg 15: 177. https://doi.org/10.3390/microorganisms9010177
[35]	Madhi SA, Anderson AS, Absalon J, et al. (2023) Potential for maternally administered vaccine for infant Group B Streptococcus. N Engl J Med 389: 215-227. https://doi.org/10.1056/NEJMoa2116045
[36]	Mahmoud A, Toth I, Stephenson R (2022) Developing an effective glycan-based vaccine for Streptococcus pyogenes. Angew Chem Int Ed 61. https://doi.org/10.1002/anie.202115342
[37]	Smeesters PR, de Crombrugghe G, Tsoi SK, et al. (2024) Global Streptococcus pyogenes strain diversity, disease associations, and implications for vaccine development: A systematic review. Lancet Microbe 5: e181-e193. https://doi.org/10.1016/S2666-5247(23)00318-X
[38]	Walkinshaw DR, Wright MEE, Mullin AE, et al. (2023) The Streptococcus pyogenes vaccine landscape. npj Vaccines 8: 16. https://doi.org/10.1038/s41541-023-00609-x
[39]	Kojima N, Konda KA, Klausner JD (2022) Notes on syphilis vaccine development. Front Immunol 13: 952284. https://doi.org/10.3389/fimmu.2022.952284
[40]	Noda AA, Méndez M, Rodríguez I, et al. (2022) Genetic recombination in treponema pallidum: implications for diagnosis, epidemiology, and vaccine development. Sex Transm Dis 49: e7-e10. https://doi.org/10.1097/OLQ.0000000000001497
[41]	Scarpini S, Morigi F, Betti L, et al. (2021) Development of a vaccine against human cytomegalovirus: advances, barriers, and implications for the clinical practice. Vaccines 9: 551. https://doi.org/10.3390/vaccines9060551
[42]	Schleiss MR, Diamond DJ (2020) Exciting times for cytomegalovirus (CMV) vaccine development: Navigating the pathways toward the goal of protecting infants against congenital CMV infection. Vaccines 8: 526. https://doi.org/10.3390/vaccines8030526
[43]	Hu X, Wang HY, Otero CE, et al. (2022) Lessons from acquired natural immunity and clinical trials to inform next-generation human cytomegalovirus vaccine development. Ann Rev Vir 9: 491-520. https://doi.org/10.1146/annurev-virology-100220-010653
[44]	Yechezkel I, Law M, Tzarum N (2021) From structural studies to HCV vaccine design. Viruses 13: 833. https://doi.org/10.3390/v13050833
[45]	Malik S, Sah R, Ahsan O, et al. (2023) Insights into the novel therapeutics and vaccines against herpes simplex virus. Vaccines 11: 325. https://doi.org/10.3390/vaccines11020325
[46]	Chentoufi A, Dhanushkodi NR, Srivastava R, et al. (2022) Combinatorial herpes simplex vaccine strategies: From bedside to bench and back. Front Immunol 13. https://doi.org/10.3389/fimmu.2022.849515
[47]	Awasthi S, Friedman HM (2021) An mRNA vaccine to prevent genital herpes. Trans Res 242: 56-65. https://doi.org/10.1016/j.trsl.2021.12.006
[48]	Stanfield BA, Kousoulas KG, Fernandez A, et al. (2021) Rational design of live-attenuated vaccines against herpes simplex viruses. Viruses 13: 1637. https://doi.org/10.3390/v13081637
[49]	Ng'uni T, Chasara C, Ndhlovu ZM (2020) Major scientific hurdles in HIV vaccine development: historical perspective and future directions. Front Immunol 11: 590780. https://doi.org/10.3389/fimmu.2020.590780
[50]	Nkolola JP, Barouch DH (2023) Prophylactic HIV-1 vaccine trials: past, present, and future. Lancet 11: E117-E124. https://doi.org/10.1016/S2352-3018(23)00264-3
[51]	Schiffner T, Phung I, Ray R, et al. (2024) Vaccination induces broadly neutralizing antibody precursors to HIV gp41. Nat Immunol 25: 1073-1082. https://doi.org/10.1038/s41590-024-01833-w
[52]	Leggat DJ, Cohen KW, Willis JR, et al. (2022) Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378: eadd6502. https://doi.org/10.1126/science.add6502
[53]	Haynes BF, Wiehe K, Borrow P, et al. (2023) Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol 23: 142-158. https://doi.org/10.1038/s41577-022-00753-w
[54]	Matarazzo L, Bettencourt PJG (2023) mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. Front Immunol 14. https://doi.org/10.3389/fimmu.2023.1172691
[55]	Suzuki H, Noguchi T, Matsugu N, et al. (2022) Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity. Vaccine 40: 6100-6106. https://doi.org/10.1016/j.vaccine.2022.09.009
[56]	Zhang Y, Li D, Lu S, et al. (2022) Toxoplasmosis vaccines: what we have and where to go?. Npj Vaccines 7: 131. https://doi.org/10.1038/s41541-022-00563-0
[57]	Wang Y, Ling L, Zhang Z, et al. (2022) Current advances in Zika vaccine development. Vaccines (Basel) 10: 1816. https://doi.org/10.3390/vaccines10111816
[58]	Pielnaa P, Al-Saadawe M, Saro A, et al. (2020) Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. Virology 543: 34-42. https://doi.org/10.1016/j.virol.2020.01.015
[59]	Mordmüller B, Sulyok M, Egger-Adam D, et al. (2019) First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria. Clin Infect Dis 69: 1509-1516. https://doi.org/10.1093/cid/ciy1140
[60]	Sirima SB, Richert L, Chêne A, et al. (2020) PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect Dis 20: 585-597. https://doi.org/10.1016/S1473-3099(19)30739-X
[61]	Kochhar S, Bonhoeffer J, Jones CE, et al. (2017) Immunization in pregnancy clinical research in low and middle income countries: study design, regulatory and safety considerations. Vaccine 35: 6575-6581. https://doi.org/10.1016/j.vaccine.2017.03.103
[62]	Centers for Disease Control and PreventionVaccine Adverse Event Reporting System (VAERS) (2021). Available from: https://vaers.hhs.gov/
[63]	Healy SA, Fried M, Richie T, et al. (2019) Malaria vaccine trials in pregnant women: An imperative without precedent. Vaccine 37: 763-770. https://doi.org/10.1016/j.vaccine.2018.12.025
[64]	U.S. Food and Drug AdministrationFDA approves first vaccine for pregnant individuals to prevent rsv in infants (2023). Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants
[65]	Centers for Disease Control and PreventionCOVID-19 vaccines while pregnant or breastfeeding (2019). Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html
[66]	Badell ML, Dude CM, Rasmussen SA, et al. (2022) COVID-19 vaccination in pregnancy. BMJ 378: e069741. https://doi.org/10.1136/bmj-2021-069741
[67]	Mitchell SL, Schulkin J, Power ML (2023) Vaccine hesitancy in pregnant women: A narrative review. Vaccine 41: 4220-4227. https://doi.org/10.1016/j.vaccine.2023.05.047
[68]	Tuckerman J, Kaufman J, Danchin M (2022) Effective approaches to combat vaccine hesitancy. Pediatr Infect Dis J 41: e243-e245. https://doi.org/10.1097/INF.0000000000003499
[69]	Kuehn M, LaMori J, DeMartino JK, et al. (2022) Assessing barriers to access and equity for COVID-19 vaccination in the US. BMC Public Health 22: 2263. https://doi.org/10.1186/s12889-022-14636-1
[70]	Howard FHN, Kwan A, Winder N, et al. (2022) Understanding immune responses to viruses-do underlying Th1/Th2 cell biases predict outcome?. Viruses 14: 1493. https://doi.org/10.3390/v14071493
[71]	Kim YH, Hong KJ, Kim H, et al. (2022) Influenza vaccines: past, present, and future. Rev Med Virol 32: e2243. https://doi.org/10.1002/rmv.2243
[72]	Aleebrahim-Dehkordi E, Molavi B, Mokhtari M, et al. (2022) T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transpl Immunol 70: 101495. https://doi.org/10.1016/j.trim.2021.101495
[73]	Rappuoli R, De Gregorio E, Costantino P (2018) On the mechanisms of conjugate vaccines. Proc Natl Acad Sci USA 116: 14-16. https://doi.org/10.1073/pnas.1819612116
[74]	Sallusto F, Lanzavecchia A, Araki K, et al. (2010) From vaccines to memory and back. Immunity 33: 451-463. https://doi.org/10.1016/j.immuni.2010.10.008
[75]	Siegrist CA (2008) Vaccine immunology. Vaccines 5: 17-36. https://doi.org/10.1016/B978-1-4160-3611-1.50006-4
[76]	Wang Q, Tan MT, Keegan BP, et al. (2014) Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation. Biomaterials 35: 8385-8393. https://doi.org/10.1016/j.biomaterials.2014.05.067
[77]	Pyzik M, Kozicky LK, Gandhi AK, et al. (2023) The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 23: 415-432. https://doi.org/10.1038/s41577-022-00821-1
[78]	Li Z, Palaniyandi S, Zeng R, et al. (2011) Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA 108: 4388-4393. https://doi.org/10.1073/pnas.1012861108
[79]	Palmeira P, Quinello C, Silveira-Lessa AL, et al. (2012) IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012: 985646. https://doi.org/10.1155/2012/985646
[80]	Li Y, Jin L, Chen T (2020) The effects of secretory IgA in the mucosal immune system. Biomed Res Int 2020: 2032057. https://doi.org/10.1155/2020/2032057
[81]	Correa VA, Portilho AI, De Gaspari E (2022) Vaccines, adjuvants and key factors for mucosal immune response. Immunology 167: 124-138. https://doi.org/10.1111/imm.13526
[82]	Mor G, Aldo P, Alvero A (2017) The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol 17: 469-482. https://doi.org/10.1038/nri.2017.64
[83]	Philbin VJ, Levy O (2009) Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 65: 98R-105R. https://doi.org/10.1203/PDR.0b013e31819f195d
[84]	Basha S, Surendran N, Pichichero M (2014) Immune responses in neonates. Expert Rev Clin Immunol 10: 1171-1184. https://doi.org/10.1586/1744666X.2014.942288
[85]	Whittaker E, Goldblatt D, McIntyre P, et al. (2018) Neonatal immunization: Rationale, current state, and future prospects. Front Immunol 9: 532. https://doi.org/10.3389/fimmu.2018.00532
[86]	Semmes EC, Chen JL, Goswami R, et al. (2021) Understanding early-life adaptive immunity to guide interventions for pediatric health. Front Immunol 11. https://doi.org/10.3389/fimmu.2020.595297
[87]	Apostol AC, Jensen KDC, Beaudin AE (2020) training the fetal immune system through maternal inflammation—A layered hygiene hypothesis. Front Immunol 11. https://doi.org/10.3389/fimmu.2020.00123
[88]	Yu JC, Khodadadi H, Malik A, et al. (2018) Innate immunity of neonates and infants. Front Immunol 9: 1759. https://doi.org/10.3389/fimmu.2018.01759
[89]	Megli CJ, Coyne CB (2022) Infections at the maternal–fetal interface: an overview of pathogenesis and defence. Nat Rev Microbiol 20: 67-82. https://doi.org/10.1038/s41579-021-00610-y
[90]	Camacho-Gonzalez A, Spearman PW, Stoll BJ (2013) Neonatal infectious diseases: evaluation of neonatal 9. Pediatr Clin North Am 60: 367-389. https://doi.org/10.1016/j.pcl.2012.12.003
[91]	Atyeo C, Alter G (2021) The multifaceted roles of breast milk antibodies. Cell 184: 1486-1499. https://doi.org/10.1016/j.cell.2021.02.031
[92]	Kumar M, Saadaoui M, Al Khodor S (2022) Infections and pregnancy: Effects on maternal and child health. Front Cell Infect Microbiol 12: 873253. https://doi.org/10.3389/fcimb.2022.873253
[93]	Yockey LJ, Lucas C, Iwasaki A (2020) Contributions of maternal and fetal antiviral immunity in congenital disease. Science 368: 608-612. https://doi.org/10.1126/science.aaz1960
[94]	Kwon S, Joshi AD, Lo CH, et al. (2021) Association of social distancing and face mask use with risk of COVID-19. Nat Commun 12: 3737. https://doi.org/10.1038/s41467-021-24115-7
[95]	Mallory ML, Lindesmith LC, Baric RS (2018) Vaccination-induced herd immunity: Successes and challenges. J Allergy Clin Immunol 142: 64-66. https://doi.org/10.1016/j.jaci.2018.05.007
[96]	Amaral E, Money D, Jamieson D, et al. (2023) Vaccination during pregnancy: A golden opportunity to embrace. Int J Gynecol Obstet 163: 476-483. https://doi.org/10.1002/ijgo.14981
[97]	Gigi CE, Anumba DOC (2021) Parvovirus B19 infection in pregnancy-A review. Eur J Obstet Gynecol Reprod Biol 264: 358-362. https://doi.org/10.1016/j.ejogrb.2021.07.046
[98]	Leruez-Ville M, Foulon I, Pass R, et al. (2020) Cytomegalovirus infection during pregnancy: state of the science. Am J Obstetrics Gynecology 223: 330-349. https://doi.org/10.1016/j.ajog.2020.02.018
[99]	Pesch MH, Schleiss MR (2022) Emerging concepts in congenital cytomegalovirus. Pediatrics 150: e2021055896. https://doi.org/10.1542/peds.2021-055896
[100]	Gerna G, Fornara C, Furione M, et al. (2021) Congenital human cytomegalovirus infection: A narrative review of maternal immune response and diagnosis in view of the development of a vaccine and prevention of primary and non-primary infections in pregnancy. Microorganisms 9: 1749. https://doi.org/10.3390/microorganisms9081749
[101]	Marchant A, Sadarangani M, Garand M, et al. (2017) Maternal immunisation: collaborating with mother nature. Lancet Infect Dis 17: e197-e208. https://doi.org/10.1016/S1473-3099(17)30229-3
[102]	Immunization Action CoalitionVaccinations for pregnant women. Available from: https://www.immunize.org/nslt.d/n63/vacs_pregnant_women.pdf
[103]	Pollard AJ, Bijker EM (2021) A guide to vaccinology: From basic principles to new developments. Nat Rev Immunol 21: 83-100. https://doi.org/10.1038/s41577-020-00479-7
[104]	World Health OrganizationGuidelines for developing a national immunization strategy. Available from: https://iris.who.int/bitstream/handle/10665/351144/WHO-IVB-2021.05-eng.pdf
[105]	Slifka MK, Amanna IJ (2018) Passive immunization. Plotkin's Vaccines . Amsterdam: Elsevier Science 84-95. e10. https://doi.org/10.1016/B978-0-323-35761-6.00008-0
[106]	Hammitt LL, Dagan R, Yuan Y, et al. (2022) Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 386: 837-846. https://doi.org/10.1056/NEJMoa2110275
[107]	Terrault NA, Levy MT, Cheung KW, et al. (2021) Viral hepatitis and pregnancy. Nat Rev Gastroenterol Hepatol 18: 117-130. https://doi.org/10.1038/s41575-020-00361-w
[108]	Lange C, Aaby P, Behr MA, et al. (2021) 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis . https://doi.org/10.1016/S1473-3099(21)00403-5
[109]	WHONew TB Vaccine Research. Available from: https://www.who.int/teams/global-tuberculosis-programme/research-innovation/vaccines
[110]	Lai R, Ogunsola AF, Rakib T, et al. (2023) Key advances in vaccine development for tuberculosis—success and challenges. npj Vaccines 8: 158. https://doi.org/10.1038/s41541-023-00750-7
[111]	Hongmin K, Han-Gyu C, Sung Jae S (2023) Bridging the gaps to overcome major hurdles in the development of next-generation tuberculosis vaccines. Front Immunol 14. https://doi.org/10.3389/fimmu.2023.1193058
[112]	Concepcion F, Estivariz MD, Link-Gelles R, et al. (2021) Poliomyelitis. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. “The Pink Book” . Washington: D.C. Public Health Foundation.
[113]	O'Ryan M (2017) Rotavirus Vaccines: a story of success with challenges ahead. F1000Res 6: 1517. https://doi.org/10.12688/f1000research
[114]	Connolly SA, Jardetzky TS, Longnecker R (2021) The structural basis of herpesvirus entry. Nat Rev Microbiol 19: 110-121. https://doi.org/10.1038/s41579-020-00448-w
[115]	Ruckwardt TJ (2023) The road to approved vaccines for respiratory syncytial virus. npj Vaccines 8: 138. https://doi.org/10.1038/s41541-023-00734-7
[116]	Barouch D (2022) COVID-19 vaccines—immunity, variants, boosters. N Engl J Med 387: 1011-1020. https://doi.org/10.1056/NEJMra2206573
[117]	Centers for Disease ControlVaccine Effectiveness: How Well Do Flu Vaccines Work?. Available from https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm
[118]	Centers for Disease ControlSelecting Viruses for the Seasonal Influenza Vaccine. Available from: https://www.cdc.gov/flu/prevent/vaccine-selection.htm
[119]	Centers for Disease Control.Use of an additional updated 2023–2024 covid-19 vaccine dose for adults aged ≥ 65 years: Recommendations of the advisory committee on immunization practices—united states, 2024. MMWR (2024) 73: 377-381. https://doi.org/10.15585/mmwr.mm7316a4
[120]	Masomian M, Ahmad Z, Gew LT, et al. (2020) Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines 8: 132. https://doi.org/10.3390/vaccines8010132
[121]	Li S, Liang H, Zhao SH, et al. (2023) Recent progress in pneumococcal protein vaccines. Front Immunol 14: 1278346. https://doi.org/10.3389/fimmu.2023.1278346
[122]	Dhama K, Dhawan M, Tiwari R, et al. (2022) COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother 18: 2045853. https://doi.org/10.1080/21645515.2022.2045853
[123]	Salloum M, Paviotti A, Bastiaens H, et al. (2023) The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023. Vaccine 41: 7076-7083. https://doi.org/10.1016/j.vaccine.2023.10.057
[124]	Matić Z, Šantak M (2022) Current view on novel vaccine technologies to combat human infectious diseases. Appl Microbiol Biotechnol 106: 25-56. https://doi.org/10.1007/s00253-021-11713-0
[125]	Zhao T, Cai Y, Jiang Y, et al. (2023) Vaccine adjuvants: mechanisms and platforms. Sig Transduct Target Ther 8: 283. https://doi.org/10.1038/s41392-023-01557-7
[126]	Rzymski P, Szuster-Ciesielska A, Dzieciątkowski T, et al. (2023) mRNA vaccines: The future of prevention of viral infections?. J Med Virol 95: e28572. https://doi.org/10.1002/jmv.28572
[127]	Nagashima KA, Mousa JJ (2021) Next-generation influenza HA immunogens and adjuvants in pursuit of a broadly protective vaccine. Viruses 13: 546. https://doi.org/10.3390/v13040546
[128]	Rappuoli R, Bottomley MJ, D'Oro U, et al. (2016) Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med 213: 469-481. https://doi.org/10.1084/jem.20151960
[129]	Pagliari S, Dema B, Sanchez-Martinez A, et al. (2023) DNA vaccines: history, molecular mechanisms and future perspectives. J Mol Biol 435: 168297. https://doi.org/10.1016/j.jmb.2023.168297
[130]	Slütter B, Jiskoot W (2016) Sizing the optimal dimensions of a vaccine delivery system: a particulate matter. Expert Opin Drug Deliv 13: 167-170. https://doi.org/10.1517/17425247.2016.1121989
[131]	Facciolà A, Visalli G, Laganà A, et al. (2022) An overview of vaccine adjuvants: Current evidence and future perspectives. Vaccines 10: 819. https://doi.org/10.3390/vaccines10050819
[132]	Nesbitt RC, Asilaza VK, Gignoux E, et al. (2024) Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan. PLoS Negl Trop Dis 18: e0011661. https://doi.org/10.1371/journal.pntd.0011661
[133]	Gigi CE, Anumba DOC (2021) Parvovirus B19 infection in pregnancy-A review. Eur J Obstet Gynecol Reprod Biol 264: 358-362. https://doi.org/10.1016/j.ejogrb.2021.07.046
[134]	Dittmer FP, Guimarães CM, Peixoto AB, et al. (2024) Parvovirus B19 infection and pregnancy: Review of the current knowledge. J Pers Med 14: 139. https://doi.org/10.3390/jpm14020139
[135]	Sartori P, Egloff C, Hcini N, et al. (2023) Primary, secondary, and tertiary prevention of congenital cytomegalovirus infection. Viruses 15: 819. https://doi.org/10.3390/v15040819
[136]	Adugna A (2023) Therapeutic strategies and promising vaccine for hepatitis C virus infection. Immun Inflamm Dis 11: e977. https://doi.org/10.1002/iid3.977
[137]	Fuerst TR, Pierce BG, Keck ZY, et al. (2018) Designing a B cell-based vaccine against a highly variable hepatitis C virus. Front Microbiol 8. https://doi.org/10.3389/fmicb.2017.02692
[138]	Zhao Q, He K, Zhang X, et al. (2022) Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review). Exp Ther Med 24: 474. https://doi.org/10.3892/etm.2022.11401

Reader Comments

Your name:*

Email:*
© 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)

AIMS Allergy and Immunology

0.4

Metrics

Article views(3931) PDF downloads(85) Cited by(0)

Preview PDF

Download XML

Export Citation

Article outline

Show full outline

Figures and Tables

Tables(2)

AIMS Allergy and Immunology

Vaccine protection of the mother, the fetus, neonates and infants

Related Papers:

Abstract

References

Reader Comments

Metrics

Figures and Tables

Other Articles By Authors

Catalog

AIMS Allergy and Immunology

Vaccine protection of the mother, the fetus, neonates and infants

Related Papers:

Abstract

References

Reader Comments

Metrics

Figures and Tables

Other Articles By Authors

Related pages

Tools

Export File

Citation

Format

Content

Catalog